Genetic Technologies Limited (GNTLF) Research

Genetic Technologies Limited, trading as GNTLF, is an Australian molecular diagnostics enterprise dedicated to creating and delivering advanced predictive assessment instruments. These tools are designed to assist medical professionals in Australia and the United States with managing women's health. The company's primary offering is BREVAGenplus, a meticulously validated risk evaluation test specifically for non-inherited breast cancer. Genetic Technologies promotes BREVAGenplus to a wide array of healthcare specialists, including those working in breast health clinics and imaging centers, obstetricians/gynecologists, and experts in breast cancer risk analysis, such as breast surgeons. Beyond this flagship product, the firm provides additional cancer risk assessment tests under the GeneType brand, specifically for Colorectal Cancer and Breast Cancer. It also has ongoing development efforts for new risk assessment diagnostics targeting various conditions, including cardiovascular disease, type 2 diabetes, prostate cancer, and melanoma. Furthermore, the company offers a comprehensive suite of genetic testing services encompassing medical, animal, forensic, and botanical applications. Established in 1987 and headquartered in Fitzroy, Australia, Genetic Technologies Limited actively engages in research and collaborative ventures with prominent institutions such as the University of Melbourne, the Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom.

Open Genetic Technologies Limited (GNTLF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.